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Background
Despite their limited licensed indications, anti-IL1
agents are often used in real-life practice for an increas-
ing number of diseases. A national survey to record
their off-label use in France was started in January 2011.
The survey is coordinated by the French National Refer-
ence Centre for Auto-Inflammatory Diseases, under the
aegis of the “Club Rhumatisme et Inflammation” (CRI).
Aims
The survey aims at gathering information concerning:
the number of patients treated with anti-IL1 agents in
France, the treated disease, the kind and the indication
of the used anti-IL1 agents, their efficacy and safety.
Methods
W es e tu pap h y s i c i a n - d i r e c t ed questionnaire available
on the website of CRI since January 2011 to December
2012, covering the following areas: patient data, disease
data, anti-IL1 agent, its efficacy, adverse events.
We advertised the study on the occasion of French
rheumatology congresses and by email to French physi-
cians that could be interested.
Any adult or paediatric patient who had received an
anti-IL1 agent before January 2005 in France could be
included.
Results
At present 94 patients from 19 centres have been
included. Main diseases were: anakinra-treated CAPS
(18), SoJIA (17), AoSD (15), gout (10), MKD (9), FMF
(6), Schnitzler’s syndrome (5).
The main off-label used agent (data known for 72
patients) was anakinra, used at least once in 66 patients.
Canakinumab was used in 15 patients. Rilonacept is not
yet available in France.
Conclusions
Data gathering on off-label use of anti-IL1 agents is
ongoing in France, with a good response from physi-
cians providing information from everyday practice.
The survey results might justify controlled clinical
trials leading to widen the licensed indications for this
class of therapeutics.
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